Medical/Pharmaceuticals

FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States

* YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications – adolescent hidradenitis suppurativa (HS) and pediatric uveitis (UV), in the U.S.[1],[2] * Pediatric UV is a rare eye inflammation in children, representing 5–10% of all uveitis...

2025-10-17 13:32 1343

Wang Qunbin: Innovation-Driven, Fosun's Path to Globalization

HONG KONG, Oct. 17, 2025 /PRNewswire/ -- On 16 October, the 2025 Sustainability Global Leaders Conference was held inShanghai. Themed "Joining Hands to Address Challenges: Global Action, Innovation, and Sustainable Growth", the Conference brought together approximately 500 guests fromChina and ab...

2025-10-17 11:17 2255

Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot

Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx  Constellation outperformed orthogonal methods in identifying select difficult-to-mapvariants SAN DIEGO, Oct. 17, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced that Gene...

2025-10-17 09:45 986

MacuMira and Keeler announce global partnership to expand Dry AMD therapy

Partnership includes manufacturing and launch in Australia and New Zealand, with  additional markets to follow. WINDSOR, England and CALGARY, AB, Oct. 17, 2025 /PRNewswire/ -- Keeler

2025-10-17 04:35 1024

A.D.A.M. Innovations and SOPHiA GENETICS partner to advance liquid biopsy testing and companion diagnostics for precision oncology in Japan

ROLLE, Switzerland and TOKYO, Oct. 16, 2025 /PRNewswire/ -- A.D.A.M. Innovations ,Japan's leading private genetic testing company, and SOPHiA GENETICS

2025-10-16 23:00 1701

Clarity signs copper-67 Supply Agreement with Nusano

SYDNEY, Oct. 16, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Supp...

2025-10-16 21:04 1496

Volpara Earns ACR® Learning Network Vendor Partner Designation

LYNNWOOD, Wash., Oct. 16, 2025 /PRNewswire/ -- Volpara Health has qualified for the American College of Radiology® (ACR®) Learning Network Vendor Partner designation. Volpara Health partnered with one of the latest graduates of the ACR ImPower Program Mammography Positioning Improvement Collaborat...

2025-10-16 21:00 1351

Cell Publishes Breakthrough Research Results of IASO Bio's Anti-BCMA CAR-T Equecabtagene Autoleucel in Autoimmune Disease Multiple Sclerosis

SHANGHAI, NANJING, China and PLEASANTON, Calif., Oct. 16, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies, today announced that theCell published results fr...

2025-10-16 20:45 1474

Unixell Biotech reported a case study of UX-DA001, an iPSC-derived autologous cell therapy for Parkinson Diseases at MDS Congress 2025

SHANGHAI, Oct. 16, 2025 /PRNewswire/ -- Unixell Biotech, a clinical-stage bitotech company focused on developing innovative cell therapies for Parkinson'sdisease (PD) and other neurological disorders, announced positive 6-month follow-up data from the first patient in its phase 1 clinical trial ...

2025-10-16 20:35 1344

SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology

BOSTON and ROLLE, Switzerland, Oct. 16, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in AI-driven precision medicine, today announced the launch of SOPHiA DDM™ Digital Twins, a breakthrough research technology that creates dynamic, virtual representations of individual patients t...

2025-10-16 16:01 1025

HARMONi-6 Phase III Study of Ivonescimab Accepted by The Lancet and Selected for ESMO 2025 LBA Presentation

HONG KONG, Oct. 16, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) today announced that the groundbreaking results from the registrational Phase III AK112-306/HARMONi-6 study of ivonescimab have been accepted for publication in The Lancet. The study evaluated ivonescimab, a first-in-class PD-1/VEGF b...

2025-10-16 12:15 1376

Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights

At ASHG, an early access customer from the London Health Sciences Center Research Institute demonstrated the power of the 5-base genome for accelerating resolution of rare disease cases  Proprietary 5-base chemistry and novel DRAGEN algorithms enable dual-omic inquiry,providing researchers with ...

2025-10-16 11:43 938

ROSTI partners with IDC to bring innovative medical device design and manufacturing capabilities

SHANGHAI, Oct. 16, 2025 /PRNewswire/ -- A report from Ringiertrade. MedTec China 2025, which took place at the Shanghai World Expo Exhibition & Convention Center (SWEECC) fromSeptember 24-26, served as the ideal platform to promote the latest innovations in the production of medical devices. At t...

2025-10-16 11:30 1214

Gene Solutions Brings Insights on Advances in MRD and Multi-Omics Technologies to the Singapore Society of Oncology Annual Scientific Meeting 2025

SINGAPORE, Oct. 15, 2025 /PRNewswire/ -- What if cancer care could move from reactive to proactive? At the Singapore Society of Oncology Annual Scientific Meeting 2025 (SSO ASM 2025),Gene Solutions showcased how Molecular Residual Disease (MRD) and AI-powered multi-om...

2025-10-16 10:30 1404

DKSH Reinforces Patient-Centric Commitment with "Patient Purpose Day 2025", Spotlighting Women's Health Equity

DKSH Business Unit Healthcare continues bringing patient centricity to life with "Patient Purpose Day 2025". This global initiative, held for the third consecutive year across 12 markets across APAC andSwitzerland, reinforces DKSH's dedication to improving patient outcomes. This year, the program...

2025-10-16 10:00 803

PENTAX Medical Announces Sale of C2 CryoBalloon™ Product Line to Merit Medical Systems through Asset Purchase Agreement

Transaction supports PENTAX Medical's strategic focus on core flexible reusable endoscopy MONTVALE, N.J., Oct. 16, 2025 /PRNewswire/ -- PENTAX Medical, a division of HOYA Group and a global leader in flexible reusable endoscopy, today announced an asset purchase agreement with Merit Medical Syst...

2025-10-16 04:05 1367

Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline

BEIJING and SHANGHAI and BOSTON, Oct. 15, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) today announced that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd. ("Beijing Jacobio"), has entered into a Capital Increase and Equity Transfer Agreement with Oceanpine Capital and an industry part...

2025-10-15 23:05 2438

TriNetX Becomes the Most Cited Real-World Data Source in Peer-Reviewed Research

With more than 2,000 citations and year-over-year growth nearing 80%, TriNetX outpaces competitors and fuels high-impact science published in top medical journals.  CAMBRIDGE, Mass., Oct. 15, 2025 /PRNewswire/ -- TriNetX, driven by its vision of a connected world where data and intelligence powe...

2025-10-15 20:34 1302

SK bioscience Files for First-in-Human Trial of Universal Coronavirus Vaccine (Pan-sarbecovirus Vaccine) GBP511 Phase 1/2 study in Australia

* Candidate designed to protect against COVID-19 variants and broader Sarbecoviruses * Phase 1/2 study to enroll ~500 healthy adults, with topline results expected by 2028 * We aim to build a universal Sarbecovirus vaccine platform to proactively address future pandemics SEONGNAM, South Kor...

2025-10-15 20:00 1212

Tamarind Health Marks Next Phase as Asia's Leading Integrated Oncology Platform

SINGAPORE, Oct. 15, 2025 /PRNewswire/ -- Tamarind Health marks the next phase in its growth asAsia's leading integrated oncology-focused healthcare platform, following the completion of its acquisition of TalkMED inSeptember 2025. A doctor-led platform built on the principle of putting patients f...

2025-10-15 17:01 1078
1 ... 32333435363738 ... 646